Revolution Medicines Catapults 30%-Plus On Upbeat Results For Pancreatic Cancer DrugInvestors Business Daily • 04/13/26
Revolution Medicines' experimental cancer pill helps improve survival in late-stage studyReuters • 04/13/26
Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trialCNBC • 04/13/26
Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancerCNBC • 04/10/26
Revolution Medicines (RVMD) Down 8.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/27/26
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/17/26
Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/03/26
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense ViewZacks Investment Research • 02/26/26
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate ProgressGlobeNewsWire • 02/25/26
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care ConferenceGlobeNewsWire • 02/24/26
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026GlobeNewsWire • 02/18/26
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 TranscriptSeeking Alpha • 02/11/26
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026GlobeNewsWire • 02/04/26
Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26